Loading...
ARPA-H-SN-26-158
Response Deadline
Oct 15, 2026, 9:00 PM(EDT)71 days
Eligibility
Contract Type
Special Notice
See attached Special Notice ARPA-H-SN-26-158: Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better outcomes in OUD (ASCENT-IBO)
This Special Notice builds upon ARPA-H-SN-26-156 and includes details related to a Proposers’ Day event.
SEE DESCRIPTION SECTION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
1301 K Street NW
Suite 1200 West
Washington, DC, 20005
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT